
The funds will go towards a new global research and development centre in Beijing’s BioPark

The biotech’s ENaBL platform enables cell therapies to be administered through an IV injection

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design of innovative small-molecule and biologic drug candidates.

SPARROW balances time and cost when optimising molecular candidates to streamline

The ability of oligonucleotides to modulate gene expression makes them an attractive modality for drugmakers

The company combines machine learning, data generation and therapeutic product development

The collaboration will see Boehringer use an IBM-developed AI model to boost its drug discovery efforts

The latest agreement builds on 20 years of collaboration between the two partners

The RKD2 test could make the early stages of drug discovery for cancer more efficient
Dr. Shahar Keinan, Co-founder & CEO of POLARIS Quantum Biotech, explores quantum computing and AI for drug discovery, the Quantum Molecular Design process, and how POLARISqb is working to improve...

Heart and circulatory diseases cause over 160,000 deaths in the UK each year

Industry partners will gain access to an extensive network of 4,000 world-leading cancer researchers